📣 VC round data is live. Check it out!

Biofrontera Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biofrontera and similar public comparables like Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics and more.

Biofrontera Overview

About Biofrontera

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.


Founded

1997

HQ

Germany

Employees

88

Financials (FY)

Revenue: $15M
EBITDA: ($653K)

EV

$13M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biofrontera Financials

Biofrontera reported last fiscal year revenue of $15M and negative EBITDA of ($653K).

In the same fiscal year, Biofrontera generated $13M in gross profit, ($653K) in EBITDA losses, and had net loss of ($5M).

Revenue (LTM)


Biofrontera P&L

In the most recent fiscal year, Biofrontera reported revenue of $15M and EBITDA of ($653K).

Biofrontera is unprofitable as of last fiscal year, with gross margin of 83%, EBITDA margin of (4%), and net margin of (30%).

See analyst estimates for Biofrontera
Last FY202320242025202620272028
Revenue$15M$38M$25M$15M
Gross Profit$13M$30M$19M$13M
Gross Margin83%81%75%83%
EBITDA($653K)($2M)($7M)($653K)
EBITDA Margin(4%)(4%)(27%)(4%)
EBIT Margin(8%)15%(27%)(8%)
Net Profit($5M)($430K)($5M)($5M)
Net Margin(30%)(1%)(20%)(30%)

Financial data powered by Morningstar, Inc.

Biofrontera Stock Performance

Biofrontera has current market cap of $17M, and enterprise value of $13M.

Market Cap Evolution


Biofrontera's stock price is $2.75.

Biofrontera share price decreased by 8.4% in the last 30 days, and increased by 3.6% in the last year.

Biofrontera has an EPS (earnings per share) of $-0.76.

See more trading valuation data for Biofrontera
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$13M$17M0.4%-8.4%-13.4%3.6%$-0.76

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biofrontera Valuation Multiples

Biofrontera trades at 0.8x EV/Revenue multiple, and (19.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Biofrontera

EV / Revenue (LTM)


Biofrontera Financial Valuation Multiples

As of May 20, 2026, Biofrontera has market cap of $17M and EV of $13M.

Biofrontera has a P/E ratio of (3.6x).

Last FY202320242025202620272028
EV/Revenue0.8x0.3x0.5x0.8x
EV/EBITDA(19.3x)(8.2x)(1.8x)(19.3x)
EV/EBIT(10.5x)2.3x(1.8x)(10.5x)
EV/Gross Profit1.0x0.4x0.7x1.0x
P/E(3.6x)(38.9x)(3.3x)(3.6x)
EV/FCF(2.4x)(3.8x)(3.9x)(2.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biofrontera Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biofrontera Margins & Growth Rates

In the most recent fiscal year, Biofrontera reported gross margin of 83%, EBITDA margin of (4%), and net margin of (30%).

See estimated margins and future growth rates for Biofrontera

Biofrontera Margins

Last FY20242025202720282029
Gross Margin83%75%83%
EBITDA Margin(4%)(27%)(4%)
EBIT Margin(8%)(27%)(8%)
Net Margin(30%)(20%)(30%)
FCF Margin(34%)(13%)(34%)

Biofrontera Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(33%)(39%)
Gross Profit Growth(37%)(33%)
EBITDA Growth344%(90%)
EBIT Growth(224%)(83%)
Net Profit Growth1079%(9%)
FCF Growth(2%)62%

Data powered by FactSet, Inc. and Morningstar, Inc.

Biofrontera Operational KPIs

Biofrontera's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Biofrontera
Last FY202320242025202620272028
Revenue per Employee$0.2M
Opex per Employee$0.2M
S&M Expenses to Revenue47%23%32%47%
G&A Expenses to Revenue24%19%46%24%
R&D Expenses to Revenue17%24%25%17%
Opex to Revenue90%66%103%90%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Biofrontera Competitors

Biofrontera competitors include Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics, Diamyd Medical, Elicera Therapeutics, Scienture Holdings, Exact Therapeutics, Poxel and AcuCort.

Most Biofrontera public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Passage Bio0.3x
AlzeCure Pharma(2.8x)(3.2x)
Neurothera Labs(86.8x)
Pasithea Therapeutics1.9x1.1x
Diamyd Medical482.7x(0.4x)(0.4x)
Elicera Therapeutics(7.5x)(6.0x)
Scienture Holdings28.5x5.6x(0.3x)
Exact Therapeutics(1.5x)

This data is available for Pro users. Sign up to see all Biofrontera competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biofrontera

When was Biofrontera founded?Biofrontera was founded in 1997.
Where is Biofrontera headquartered?Biofrontera is headquartered in Germany.
How many employees does Biofrontera have?As of today, Biofrontera has over 88 employees.
Is Biofrontera publicly listed?Yes, Biofrontera is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Biofrontera?Biofrontera trades under B8FK ticker.
When did Biofrontera go public?Biofrontera went public in 2007.
Who are competitors of Biofrontera?Biofrontera main competitors include Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics, Diamyd Medical, Elicera Therapeutics, Scienture Holdings, Exact Therapeutics, Poxel, AcuCort.
What is the current market cap of Biofrontera?Biofrontera's current market cap is $17M.
What is the current revenue of Biofrontera?Biofrontera's last fiscal year revenue is $15M.
What is the current EV/Revenue multiple of Biofrontera?Current revenue multiple of Biofrontera is 0.8x.
Is Biofrontera profitable?No, Biofrontera is not profitable.
How many companies Biofrontera has acquired to date?Biofrontera hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Biofrontera has invested to date?Biofrontera hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biofrontera

Lists including Biofrontera

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial